P1350 - Increasing Prevalence of Eosinophilic Esophagitis in the United States from 2015 to 2018

Monday, October 25, 2021

10:30 AM – 4:15 PM PT

Location: Shoreline Exhibit Hall

Has Audio

Presenting Author(s)

Eilish McCann, PhD

Siddhesh Kamat, MS, MBA¹, Degang Wang, PhD¹, Urvi Mujumdar, PhD², Eilish McCann, PhD³, Chien-Chia Chuang, PhD, MSc², Jessica Jalbert, PhD¹, Mirna Chehade, MD, MPH⁴
¹Regeneron Pharmaceuticals, New York, NY; ²Sanofi Genzyme, Cambridge, MA; ³Regeneron Pharmaceuticals, Tarrytown, NY; ⁴Mount Sinai Center for Eosinophilic Disorders, Icahn School of Medicine at Mount Sinai, New York, NY

Introduction: Prevalence of eosinophilic esophagitis (EoE) has greatly increased over the past two decades, in part due to increased awareness and improved disease detection. As recent estimates of EoE in the US are lacking, the aim of this study was to estimate the annual prevalence of diagnosed EoE in the US from 2015 through 2018, overall and by age and sex.

Methods: Data from the Truven MarketScan^® Commercial/Medicare databases were used to identify patients with >1 ICD-9/10 code for EoE. The database includes geographically and demographically representative data covering approximately 19–21 million US enrollees of commercial and/or Medicare plans annually between 2015–2018. Annual prevalence of EoE from 2015 through 2018 was calculated by dividing the number of patients with an EoE diagnosis each year by the total number of healthcare plan enrollees continuously enrolled in that year, multiplied by 100,000. Annual prevalence of EoE was reported by year of diagnosis (i.e., 2015, 2016, 2017, and 2018), and the prevalence in 2018 was stratified by age and sex.

Results: The number of patients diagnosed with EoE ranged from 16,980 in 2015 to 22,978 in 2018. Annual prevalence of EoE increased over time, from 79 per 100,000 enrollees in 2015 to 117 per 100,000 in 2018 (Figure 1A). In 2018, overall prevalence was 68 per 100,000 for children aged under 10 years, ranged from 115–123 per 100,000 for children and adolescents aged 10–19 years, ranged from 93–164 per 100,000 for adults aged 20–64 years, and was 57 per 100,000 for older adults aged over 65 years (Figure 1B). When stratified by 5-year age increments, prevalence of EoE in 2018 was highest in patients aged between 35 and 44 years (159–164 per 100,000; Figure 1B). EoE prevalence was consistently higher in males versus females across all age groups (Figure 1B); overall, prevalence in 2018 was almost two-fold higher for males versus females (151 vs 86 per 100,000 enrollees).

Discussion: Annual prevalence of EoE in the US has increased in recent years. EoE is more prevalent in male patients and peaks among patients aged 35–44 years.

Figure: Figure 1. Prevalence of EoE in the US (A) from 2015 through 2018, and (B) in 2018, stratified by age and sex

Disclosures:

Siddhesh Kamat: Regeneron Pharmaceuticals Inc. – Employee, Stockholder/Ownership Interest (excluding diversified mutual funds).

Degang Wang: Regeneron Pharmaceuticals Inc. – Employee, Stockholder/Ownership Interest (excluding diversified mutual funds).

Urvi Mujumdar: Sanofi Genzyme – Employee, Stockholder/Ownership Interest (excluding diversified mutual funds).

Eilish McCann: Regeneron Pharmaceuticals Inc. – Employee, Stockholder/Ownership Interest (excluding diversified mutual funds).

Chien-Chia Chuang: Sanofi Genzyme – Employee, Stockholder/Ownership Interest (excluding diversified mutual funds).

Jessica Jalbert: Regeneron Pharmaceuticals Inc. – Employee, Stockholder/Ownership Interest (excluding diversified mutual funds).

Mirna Chehade: Adare – Consultant. Allakos – Consultant, Grant/Research Support. AstraZeneca – Consultant, Grant/Research Support. Bristol Myers Squibb – Consultant. Danone – Grant/Research Support. Regeneron Pharmaceuticals Inc. – Consultant, Grant/Research Support. Sanofi Genzyme – Consultant. Shire/Takeda – Consultant, Grant/Research Support.

Siddhesh Kamat, MS, MBA¹, Degang Wang, PhD¹, Urvi Mujumdar, PhD², Eilish McCann, PhD³, Chien-Chia Chuang, PhD, MSc², Jessica Jalbert, PhD¹, Mirna Chehade, MD, MPH⁴. P1350 - Increasing Prevalence of Eosinophilic Esophagitis in the United States from 2015 to 2018, ACG 2021 Annual Scientific Meeting Abstracts. Las Vegas, Nevada: American College of Gastroenterology.